Clinical Trials Logo

Clinical Trial Summary

Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination


Clinical Trial Description

Prospective observational study to evaluate a possible change in antiphospholipid antibody profiles after coronavirus disease 2019 (COVID-19) infection or vaccination. Patients with antiphospholipid syndrome (APS) with thromboembolic complications recorded using the retrospective database of the APSANTICO registry (ClinicalTrials.gov Identifier: NCT05195372) will serve as a baseline for a prospective observational study to investigate the extent to which COVID 19 infection and/or COVID 19 vaccination alters APS antibody profiles. Current literature suggests that patients who have been or are infected with COVID-19 are at higher risk of thrombosis. This increased risk is due to, among other things, damaged endothelium, slower blood flow and observed hypercoagulability of the blood. It has also been described that COVID-19 patients may have a higher prevalence of lupus anticoagulant. Based on these assumptions, one of the aims of the prospective observational study is to determine whether and to what extent COVID-19 infection affects the antibody profile of APS patients. In addition, atypical thrombosis with thrombocytopenia has been repeatedly reported recently as a rare side effect after COVID-19 vaccination with two recombinant adenoviral vectors encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca and Ad26.COV2.S, Johnson&Johnson). The extent to which thrombosis could also occur after messenger RNA (mRNA) vaccines has not yet been clearly proven. Furthermore, it is unclear whether COVID-19 infections and/or vaccinations can possibly influence the expression and level of antiphospholipid antibody titres. Therefore, another aim of the prospective observational study is to compare the antiphospholipid antibody results available from the retrospective registry before COVID-19 vaccination or COVID-19 infection with the antibody results after COVID-19 infection and/or vaccination. For this purpose, the patients who were recorded in the retrospective register are contacted by post with an information letter and then called in by telephone to the investigators coagulation centre for a follow-up examination after the COVID-19 vaccinations have been carried out and/or after COVID-19 infection. Then, during this examination, a blood sample is taken to monitor the course of the antiphospholipid antibodies. In addition, patients are offered a test of COVID-19 nucleocapsid antibodies and COVID-19 spike antibodies free of charge to check the success of the vaccination. This is of particular interest as some of these patients are taking immunosuppressive drugs due to an underlying autoimmune disease, which could weaken the immune response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05313048
Study type Observational [Patient Registry]
Source Cardioangiologisches Centrum Bethanien
Contact
Status Completed
Phase
Start date March 15, 2022
Completion date October 24, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04997551 - Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19 Phase 3
Recruiting NCT04977024 - SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Phase 2
Completed NCT05049226 - Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Terminated NCT04455815 - A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) Phase 2
Completed NCT04662437 - The Status of Parathyroid Hormone Secretion in Covid-19 Patients
Recruiting NCT05792878 - Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
Completed NCT04659200 - Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
Recruiting NCT04470583 - Evaluating Clinical Parameters of COVID-19 in Pregnancy
Withdrawn NCT04377568 - Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Phase 2
Completed NCT04848610 - The Factors That Affect the Infection of COVID-19
Recruiting NCT04582903 - Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Recruiting NCT06032000 - Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203) Phase 1
Terminated NCT04941703 - "CHANGE COVID-19 Severity" Phase 1/Phase 2
Active, not recruiting NCT04639466 - A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection Phase 1/Phase 2
Completed NCT04575038 - CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19 Phase 2
Recruiting NCT05022446 - The Impact of COVID-19 on Pulmonary Procedures
Completed NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Active, not recruiting NCT04650178 - Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
Recruiting NCT04169542 - Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery